John W. Chang-Ho

Linkou Branch
Taoyuan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564].

Corrigendum to 'Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial' [Journal of Thoracic Oncology volume 21 issue 6 (2026) 103564].

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 24, 2026

Correction: Wu et al. WIP1 Inhibition by GSK2830371 Potentiates HDM201 Through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells. Cancers 2021, 13, 3876.

Correction: Wu et al. WIP1 Inhibition by GSK2830371 Potentiates HDM201 Through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells. Cancers 2021, 13, 3876.

Journal: Cancers

Published: January 26, 2026

Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial.

Patient-Reported Outcomes With Consolidation Durvalumab Versus Placebo After Concurrent Chemoradiotherapy in Limited-Stage SCLC: Results From the Phase 3 ADRIATIC Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: September 04, 2025

Ocular manifestations in Stevens‒Johnson syndrome/toxic epidermal necrolysis in cancer patients.

Ocular manifestations in Stevens‒Johnson syndrome/toxic epidermal necrolysis in cancer patients.

Journal: The ocular surface

Published: March 10, 2025

Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort Study.

Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort Study.

Journal: Clinical Medicine Insights. Oncology

Published: October 29, 2024

Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study.

Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study.

Journal: Therapeutic advances in medical oncology

Published: October 17, 2024

Integrating comprehensive genomic profiling in the management of oncology patients: Applications and challenges in Taiwan.

Integrating comprehensive genomic profiling in the management of oncology patients: Applications and challenges in Taiwan.

Journal: Biomedical journal

Published: September 27, 2024

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.

Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.

Journal: The New England journal of medicine

Published: September 13, 2024

Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy.

Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: August 12, 2024

Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib.

Baseline and changes in inflammatory parameters for patients with EGFR-mutated NSCLC treated with afatinib.

Journal: Thoracic cancer

Published: February 15, 2024

Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade.

Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade.

Journal: Nature communications

Published: January 04, 2024

First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.

First-line pembrolizumab-axitinib versus sunitinib in metastatic RCC: subgroup analysis of patients enrolled in the phase 3 KEYNOTE-426 in Eastern Asia.

Journal: Japanese journal of clinical oncology

Published: November 08, 2023

Showing 1-12 of 90

Last Updated: 09/26/2026